Table 2.
Seropositivity following full-dose yellow fever (YF) vaccination in children.
Study Vaccine | Population | Type | Test and seropositivity criteria | Time post vaccination | Seropositive | |
---|---|---|---|---|---|---|
No. | (%) | |||||
López 201658 17D-204 (France) |
Endemic | RCT |
PRNT50 Titer ≥10 |
1m | 594/595 | (99.8) |
Chowdhury 2015a59 17DD (Brazil)Ghana 17D-213 (Russia)Mali |
Endemic | RCT |
Micro-PRNT50 Titer ≥8 |
1m |
841G 300M |
(68–79)G (95–98)M |
Domingo 201934 17DD (Brazil)Ghana 17D-213 (Russia)Mali |
Endemic | RCT |
Micro-PRNT90 ≥0.5 IU/mLb |
2.3y 4.5y 6y |
121/436G 296/587M 188/436G |
(28)G (50)M (43)G |
De Noronha 2019c33 17DD (Brazil) | Endemic | Obs |
Micro-PRNT50 Titer ≥10 |
0–6m 1y 2y 4y 7y 10y |
143/165 107/140 97/136 72/122 57/135 58/126 |
(87) (76) (71) (59) (42) (46) |
G Ghana, M Mali, Obs observational, PRNT plaque reduction neutralization test, RCT randomized control trial, IU international units, m months, y years.
aNumbers represent the number of children with immunogenicity results included in the respective countries (denominator) and proportions represent those seroconverting; 64–68% of children in Ghana (N = 38) and 90–98% of children in Mali (n = 12) were seropositive at baseline and had ≥2-fold increase in antibody titer.
bData from vaccinees were also presented in the same paper using any detectable antibodies. The proportion of seropositive was higher for all groups: 39% (172/436) at 2.3 years in Ghana; 70% (409/587) seropositivity at 4.5 years in Mali; and 51% (223/436) seropositivity at 6 years in Ghana.
cSame data presented in Campi-Azevedo et al. (2019)55.